Search

Welcome to the Division of Chemical & Systems Biology

Home > Research Groups > Barth Group

Barth Group

BARTH, Prof Dr Dr Stefan - Position presently held
South African Research Chair in Cancer Biotechnology, Tier 1

Main areas of research/expertise
Medical biotechnology, antibody technologies, protein engineering, immunodiagnostics, bioassay development & integration, immunotherapeutics, targeted human cytolytic fusion proteins, SNAP-tag based fusion proteins, ex vivo / in vivo targeting

Biosketch
Tier 1 South African Research Chair in Cancer Biotechnology hosted by the Institute of Infectious Disease and Molecular Medicine (IDM) and the Department of Integrated Biomedical Sciences, awarded by the South African Research Chairs Initiative (SARChI) of the Department of Science and Technology (DST), administered through the National Research Foundation (NRF) (since 2015). Full professor in the Department of Integrated Biomedical Sciences at University of Cape Town and full member at the Institute for Infectious Disease and Molecular Medicine IDM (since 2015). University Professor for Experimental Medicine and Immunotherapy at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Germany (2006-2015). Head of Department of Pharmaceutical Product Development at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Aachen, Germany (2000-2015). Habilitation in Experimental Internal Medicine (2001), DMSc in Experimental Medicine (Dr. rer. medic.) at the Department of Internal Medicine, University of Cologne, Germany (1997), PhD in biology (Dr. rer. nat.) at the Institute of Molecular Physiology and Biotechnology of Plants, University of Bonn, Germany (1994), MSc in Biology at the University of Bonn, Germany (1991).

Prof. Barth is co-founder of CURIT Biotech Holding GmbH (HRB 16028); was co-founder of Pharmedartis GmbH (HRB 13916) and TOXAVIS GmbH (HRB 61471; financing POCDIA GmbH (HRB 9178) and TOXAVIS Pharmaceuticals GmbH (HRB 62750)), start-up companies in the areas of biotechnology and medical technologies. He became member in different scientific societies including e.g. German Society for Hematology and Oncology, German Cancer Society, and European Association for Cancer Research. He is appointed reviewer for different funding societies including German Research Foundation (DFG), Alexander von Humboldt-Foundation, Wilhelm Sander Foundation, Bavarian Research Foundation, Swiss National Science Foundation, Austrian Science Fund, Dutch Cancer Society, Worldwide Cancer Research. He is also acting as reviewer for different scientific journals inclunding Cancer Letters, Biological Chemistry, Bioconjugate Chemistry, Molecular Cancer Therapeutics, Haematologica, Journal of Controlled Release, International Journal of Cancer, PLOS ONE, Cancer Research, Clinical Cancer Research, Molecular Oncology, Apoptosis, mAbs, and Nature Methods. He received several prizes for conference contributions, for business concepts and very recently 1st prize of the Boehringer Ingelheim Innocentive Challenge together with Frank Brombacher and Frank Kirstein.